Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Cite this paper

@article{Kvols2012PasireotideS, title={Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.}, author={Larry K. Kvols and Kjell E Oberg and Thomas M O'dorisio and Pharis Mohideen and Wouter W. de Herder and Rudolf Arnold and Ke Hu and Yilong Zhang and Gareth Hughes and Lowell B. Anthony and Bertram Wiedenmann}, journal={Endocrine-related cancer}, year={2012}, volume={19 5}, pages={657-66} }